経口経粘膜薬の世界市場：シェア、規模、動向、産業分析レポート - 製品タイプ別、投与経路別、適応症別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

経口経粘膜薬の世界市場規模は2032年までに829億9,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

研究開発努力の急増は、新製品の発売や対象疾患の有病率の増加と相まって、市場成長を促進する構えです。さらに、対象人口の増加が市場拡大に寄与すると予想されます。口腔経粘膜フェンタニルクエン酸塩のユニークな製剤は、頬粘膜からのドラッグデリバリーのためにフェンタニルをロゼンジに組み込んだもので、初回通過代謝をバイパスすることにより、経口経路に比べてバイオアベイラビリティが向上しています。

その結果、様々な障害に伴う痛みの即時緩和を求める患者集団におけるオピオイド依存の高まりが、経口経粘膜薬剤の需要を促進する可能性が高いです。例えば、2021年の世界保健機関のデータによると、世界全体で約2億7,500万人が薬剤を使用しており、そのうち約6,200万人がオピオイドを使用しています。

パーキンソン病（PD）と片頭痛の有病率の増加は、市場拡大の原動力になると予想されます。例えば、2022年1月に発表されたParkinson's Foundationのデータによると、米国では現在約1,000万人がパーキンソン病を患っており、2030年には約120万人に増加すると予測されています。パーキンソン病は、アルツハイマー病に次いで2番目に多い神経変性疾患であり、毎年6万人以上のアメリカ人がパーキンソン病と診断されています。このような疾患の罹患率の増加は、経口経粘膜剤の治療への採用を後押しし、疼痛管理の改善と即時の緩和につながると思われます。

2021年1月現在、CDCのデータによると、米国では65歳以上の成人の26％が8本以下の歯しかなく、同年齢層の成人の約6人に1人（17％）がすべての歯を失っています。さらに、2022年2月のCDCのデータによると、米国では18歳以上の成人の63％が過去1年間に歯科を受診しており、2～17歳の子供の85.9％が2020年に歯科を受診しています。このような歯科受診の増加は、ミダゾラムやブプレノルフィンといった鎮静・鎮痛用の経口経粘膜薬の需要を促進すると予想されます。

経口経粘膜薬市場レポートハイライト

使いやすさ、吸収のしやすさ、効率の高さから錠剤が最大シェア

オピオイド依存症が市場を席巻しているが、これは主にオピオイド障害の増加によるものです。

舌下薬は急性疼痛時に好まれるため、最大シェアを獲得

APACは、ストレスや精神状態に苦しむ人口が多いため、最も速い速度で成長すると予想されます。

市場参入企業には、Aquestive Therapeutics、C.L. Pharm、GW Pharmaceuticals、IntelGenx、Pfizer、Seoul Pharmaceuticals、Shilpa Therapeuticsなどがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の経口経粘膜薬市場に関する洞察

• 経口経粘膜薬 - 業界スナップショット
• 経口経粘膜薬市場力学
  • 促進要因と機会
    • ヘルスケアにおける経口経粘膜薬技術の使用の増加
    • 技術の進歩
  • 抑制要因と課題
    • デジタル化の進展により市場の成長が制限される
• PESTLE分析
• 経口経粘膜薬業界の動向
• バリューチェーン分析
• COVID-19感染症の影響分析

第5章 世界の経口粘膜薬市場：製品タイプ別

• 主な調査結果
• イントロダクション
• 錠剤
• フィルム
• 液体・スプレー
• その他

第6章 世界の経口経粘膜薬市場：投与経路別

• 主な調査結果
• イントロダクション
• 舌下粘膜
• その他

第7章 世界の経口経粘膜薬市場：適応症別

• 主な調査結果
• イントロダクション
• オピオイド依存症
• 吐き気と嘔吐
• 勃起不全
• 神経学的障害
• その他

第8章 世界の経口経粘膜薬市場：流通チャネル別

• 主な調査結果
• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界の経口経粘膜薬市場：地域別

• 主な調査結果
• イントロダクション
  • 経口経粘膜薬市場評価：地域別（2019年～2032年）
• 経口経粘膜薬市場 - 北米
  • 製品タイプ別（2019年～2032年）
  • 流通チャネル別（2019年～2032年）
  • 投与経路別（2019年～2032年）
  • 適応症別（2019年～2032年）
  • 米国
  • カナダ
• 経口経粘膜薬市場 - 欧州
  • 製品タイプ別（2019年～2032年）
  • 流通チャネル別（2019年～2032年）
  • 投与経路別（2019年～2032年）
  • 適応症別（2019年～2032年）
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
• 経口経粘膜薬市場 - アジア太平洋
  • 製品タイプ別（2019年～2032年）
  • 流通チャネル別（2019年～2032年）
  • 投与経路別（2019年～2032年）
  • 適応症別（2019年～2032年）
  • 中国
  • インド
  • 日本
  • マレーシア
  • インドネシア
  • 韓国
• 経口経粘膜薬市場 - 中東・アフリカ
  • 製品タイプ別（2019年～2032年）
  • 流通チャネル別（2019年～2032年）
  • 投与経路別（2019年～2032年）
  • 適応症別（2019年～2032年）
  • サウジアラビア
  • 南アフリカ
  • イスラエル
  • アラブ首長国連邦
• 経口経粘膜薬市場 - ラテンアメリカ
  • 製品タイプ別（2019年～2032年）
  • 流通チャネル別（2019年～2032年）
  • 投与経路別（2019年～2032年）
  • 適応症別（2019年～2032年）
  • メキシコ
  • ブラジル
  • アルゼンチン

第10章 競合情勢

• 拡張と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第11章 企業プロファイル

• Aquestive Therapeutics, Inc
• C.L.Pharm Co., Ltd
• GW Pharmaceuticals plc
• IntelGenx Corp
• IntelGenx Corp
• Pfizer Inc
• Seoul Pharmaceuticals
• Shilpa Therapeutics
• Sunovion Pharmaceuticals, Inc.
• ZIM Laboratories Limited

List of Tables

• Table 1 Global Oral Transmucosal Drugs Market, by Product Distribution Channel, by Region, 2019-2032 (USD Billion)
• Table 2 Global Oral Transmucosal Drugs Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
• Table 3 Global Oral Transmucosal Drugs Market, by Indication, by Region, 2019-2032 (USD Billion)
• Table 4 Global Oral Transmucosal Drugs Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
• Table 5 Oral Transmucosal Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
• Table 6 North America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 7 North America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 8 North America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 9 North America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 10 U.S.: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 11 U.S.: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 12 U.S.: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 13 U.S.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 14 Canada: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 15 Canada: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 16 Canada: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 17 Canada: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 18 Europe: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 19 Europe: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 20 Europe: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 21 Europe: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 22 Germany: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 23 Germany: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 24 Germany: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 25 Germany: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 26 France: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 27 France: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 28 France: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 29 France: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 30 UK: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 31 UK: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 32 UK: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 33 UK: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 34 Italy: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 35 Italy: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 36 Italy: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 37 Italy: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 38 Netherlands: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 39 Netherlands: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 40 Netherlands: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 41 Netherlands: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 42 Spain: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 43 Spain: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 44 Spain: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 45 Spain: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 46 Russia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 47 Russia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 48 Russia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 49 Russia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 50 Asia Pacific: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 51 Asia Pacific: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 52 Asia Pacific: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 53 Asia Pacific: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 54 China: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 55 China: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 56 China: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 57 China: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 58 Japan: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 59 Japan: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 60 Japan: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 61 Japan: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 62 India: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 63 India: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 64 India: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 65 India: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 66 Indonesia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 67 Indonesia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 68 Indonesia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 69 Indonesia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 70 Malaysia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 71 Malaysia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 72 Malaysia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 73 Malaysia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 74 South Korea: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 75 South Korea: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 76 South Korea: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 77 South Korea: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 78 Latin America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 79 Latin America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 80 Latin America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 81 Latin America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 82 Brazil: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 83 Brazil: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 84 Brazil: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 85 Brazil: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 86 Mexico: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 87 Mexico: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 88 Mexico: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 89 Mexico: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 90 Argentina: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 91 Argentina: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 92 Argentina: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 93 Argentina: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 94 Middle East & Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 95 Middle East & Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 96 Middle East & Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 97 Middle East & Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 98 UAE: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 99 UAE: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 100 UAE: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 101 UAE: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 102 Saudi Arabia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 103 Saudi Arabia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 104 Saudi Arabia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 105 Saudi Arabia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 106 South Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 107 South Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 108 South Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 109 South Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 110 Israel: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• Table 111 Israel: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 112 Israel: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• Table 113 Israel: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

• Figure 1. Global Oral Transmucosal Drugs Market, 2019-2032 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Product Distribution Channel
• Figure 7. Global Oral Transmucosal Drugs Market, by Product Distribution Channel, 2021 & 2030 (USD Billion)
• Figure 8. Market by Distribution Channel
• Figure 9. Global Oral Transmucosal Drugs Market, by Distribution Channel, 2021 & 2030 (USD Billion)
• Figure 10. Market by Route of Administration
• Figure 11. Global Oral Transmucosal Drugs Market, by Route of Administration, 2021 & 2030 (USD Billion)
• Figure 12. Market by Indication
• Figure 13. Global Oral Transmucosal Drugs Market, by Indication, 2021 & 2030 (USD Billion)

The global oral transmucosal drugs market size is expected to reach USD 82.99 billion by 2032, according to a new study by Polaris Market Research. The report "Oral Transmucosal Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Tablets, Films), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The surge in research and development endeavors, coupled with new product launches and an increase in the prevalence of targeted diseases, is poised to propel market growth. Additionally, the growth in the target population is expected to contribute to the market's expansion. The unique formulation of oral transmucosal fentanyl citrate, incorporating fentanyl in a lozenge for drug delivery through the buccal mucosa, offers enhanced bioavailability compared to the oral route by bypassing first-pass metabolism.

Consequently, the growing opioid dependence within the patient population seeking immediate relief from pain associated with various disorders is likely to drive the demand for oral transmucosal drugs, for example, as per the World Health Organization's data from 2021, around 275 million people globally used medications, with approximately 62 million among them using opioids.

The growing prevalence of Parkinson's disease (PD) and migraine is anticipated to drive the expansion of the market. For instance, data from the Parkinson's Foundation, January 2022, reveals that nearly one million people in the United States are currently living with Parkinson's disease, with projections indicating an increase to around 1.2 Mn by 2030. Parkinson's disease stands as the second-most common neurodegenerative disease, following Alzheimer's disease, with over 60,000 Americans diagnosed annually and a global population exceeding 10 Mn individuals living with PD. The rising incidences of such disorders are likely to boost the adoption of oral transmucosal drugs for their treatment, leading to improved pain management and immediate relief.

As of January 2021, data from the CDC indicates that 26% of adults aged 65 or older had eight or fewer teeth, and approximately 1 in 6 (17%) adults in the same age group had lost all their teeth in the United States. Additionally, according to CDC data from February 2022, 63% of adults aged 18 and over in the United States had a dental visit in the past year, and 85.9% of children aged 2-17 years had a dental visit in the year 2020. This rise in dental visits is expected to fuel the demand for oral transmucosal drugs, such as midazolam and buprenorphine, for sedation and pain relief.

Oral Transmucosal Drugs Market Report Highlights

Tablets segment held the largest share, owing to its ease of use, easy absorption, and have higher efficiency

Opioid dependence segment dominated the market, primarily due to rising cases of opioid disorders

Sub-lingual drugs garnered the largest share, as they are mostly preferred during acute pain conditions

APAC expected to grow at the fastest rate, due to presence of huge population suffering with stress and mental conditions

The market players include Aquestive Therapeutics, C.L. Pharm, GW Pharmaceuticals, IntelGenx, Pfizer, Seoul Pharmaceuticals, and Shilpa Therapeutics

Polaris Market Research has segmented the oral transmucosal drugs market report based on product type, route of administration, indication, distribution channel, and region:

Oral Transmucosal Drugs, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Tablets
• Films
• Liquid & Spray
• Others

Oral Transmucosal Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

• Sublingual Mucosa
• Buccal Mucosa
• Others

Oral Transmucosal Drugs, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

• Opioid Dependence
• Nausea and Vomiting
• Erectile Dysfunction
• Neurological Disorders
• Others

Oral Transmucosal Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Oral Transmucosal Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1.Introduction

• 1.1.Report Description
  • 1.1.1.Objectives of the Study
  • 1.1.2.Market Scope
  • 1.1.3.Assumptions
• 1.2.Stakeholders

2.Executive Summary

• 2.1.Market Highlights

3.Research Methodology

• 3.1.Overview
  • 3.1.1.Data Mining
• 3.2.Data Sources
  • 3.2.1.Primary Sources
  • 3.2.2.Secondary Sources

4.Global Oral Transmucosal Drugs Market Insights

• 4.1.Oral Transmucosal Drugs - Industry Snapshot
• 4.2.Oral Transmucosal Drugs Market Dynamics
  • 4.2.1.Drivers and Opportunities
    • 4.2.1.1.Increasing use of Oral Transmucosal Drugs technology in healthcare
    • 4.2.1.2.Technological advancement
  • 4.2.2.Restraints and Challenges
    • 4.2.2.1.Increasing digitization will restrict the market growth
• 4.3.Porter's Five Forces Analysis
  • 4.3.1.Bargaining Power of Suppliers (Moderate)
  • 4.3.2.Threats of New Entrants: (Low)
  • 4.3.3.Bargaining Power of Buyers (Moderate)
  • 4.3.4.Threat of Substitute (Moderate)
  • 4.3.5.Rivalry among existing firms (High)
• 4.4.PESTLE Analysis
• 4.5.Oral Transmucosal Drugs Industry Trends
• 4.6.Value Chain Analysis
• 4.7.COVID-19 Impact Analysis

5.Global Oral Transmucosal Drugs Market, by Product Distribution Channel

• 5.1.Key Findings
• 5.2.Introduction
  • 5.2.1.Global Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
• 5.3.Tablets
  • 5.3.1.Global Oral Transmucosal Drugs Market, by Tablets, by Region, 2019-2032 (USD Billion)
• 5.4.Films
  • 5.4.1.Global Oral Transmucosal Drugs Market, by Films, by Region, 2019-2032 (USD Billion)
• 5.5.Liquid & Spray
  • 5.5.1.Global Oral Transmucosal Drugs Market, by Liquid & Spray, by Region, 2019-2032 (USD Billion)
• 5.6.Others
  • 5.6.1.Global Oral Transmucosal Drugs Market, by Others , by Region, 2019-2032 (USD Billion)

6.Global Oral Transmucosal Drugs Market, by Route of Administration

• 6.1.Key Findings
• 6.2.Introduction
  • 6.2.1.Global Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 6.3.Sublingual Mucosa
  • 6.3.1.Global Oral Transmucosal Drugs Market, by Sublingual Mucosa, by Region, 2019-2032 (USD Billion)
• 6.4.Sublingual Mucosa
  • 6.4.1.Global Oral Transmucosal Drugs Market, by Sublingual Mucosa, by Region, 2019-2032 (USD Billion)
• 6.5.Others
  • 6.5.1.Global Oral Transmucosal Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7.Global Oral Transmucosal Drugs Market, by Indication

• 7.1.Key Findings
• 7.2.Introduction
  • 7.2.1.Global Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• 7.3.Opioid Dependence
  • 7.3.1.Global Oral Transmucosal Drugs Market, by Opioid Dependence, by Region, 2019-2032 (USD Billion)
• 7.4.Nausea and Vomiting
  • 7.4.1.Global Oral Transmucosal Drugs Market, by Nausea and Vomiting, by Region, 2019-2032 (USD Billion)
• 7.5.Erectile Dysfunction
  • 7.5.1.Global Oral Transmucosal Drugs Market, by Erectile Dysfunction, by Region, 2019-2032 (USD Billion)
• 7.6.Neurological Disorders
  • 7.6.1.Global Oral Transmucosal Drugs Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
• 7.7.Others
  • 7.7.1.Global Oral Transmucosal Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

8.Global Oral Transmucosal Drugs Market, by Distribution Channel

• 8.1.Key Findings
• 8.2.Introduction
  • 8.2.1.Global Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.3.Hospital Pharmacies
  • 8.3.1.Global Oral Transmucosal Drugs Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Billion)
• 8.4.Retail Pharmacies
  • 8.4.1.Global Oral Transmucosal Drugs Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
• 8.5.Online Pharmacies
  • 8.5.1.Global Oral Transmucosal Drugs Market, by Online Pharmacies, by Region, 2019-2032 (USD Billion)

9.Global Oral Transmucosal Drugs Market, by Geography

• 9.1.Key findings
• 9.2.Introduction
  • 9.2.1.Oral Transmucosal Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
• 9.3.Oral Transmucosal Drugs Market - North America
  • 9.3.1.North America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 9.3.2.North America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.3.3.North America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.3.4.North America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.3.5.Oral Transmucosal Drugs Market - U.S.
    • 9.3.5.1.U.S.: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.5.2.U.S.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.5.3.U.S.: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.5.4.U.S.: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.3.6.Oral Transmucosal Drugs Market - Canada
    • 9.3.6.1.Canada: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.6.2.Canada: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.6.3.Canada: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.6.4.Canada: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• 9.4.Oral Transmucosal Drugs Market - Europe
  • 9.4.1.Europe: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 9.4.2.Europe: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.4.3.Europe: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.4.Europe: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.5.Oral Transmucosal Drugs Market - UK
    • 9.4.5.1.UK: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.5.2.UK: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.5.3.UK: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.5.4.UK: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.6.Oral Transmucosal Drugs Market - France
    • 9.4.6.1.France: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.6.2.France: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.6.3.France: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.6.4.France: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.7.Oral Transmucosal Drugs Market - Germany
    • 9.4.7.1.Germany: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.7.2.Germany: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.7.3.Germany: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.7.4.Germany: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.8.Oral Transmucosal Drugs Market - Italy
    • 9.4.8.1.Italy: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.8.2.Italy: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.8.3.Italy: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.8.4.Italy: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.9.Oral Transmucosal Drugs Market - Spain
    • 9.4.9.1.Spain: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.9.2.Spain: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.9.3.Spain: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.9.4.Spain: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.10.Oral Transmucosal Drugs Market - Netherlands
    • 9.4.10.1.Netherlands: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.10.2.Netherlands: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.10.3.Netherlands: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.10.4.Netherlands: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.4.11.Oral Transmucosal Drugs Market - Russia
    • 9.4.11.1.Russia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.11.2.Russia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.11.3.Russia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.11.4.Russia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• 9.5.Oral Transmucosal Drugs Market - Asia Pacific
  • 9.5.1.Asia Pacific: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 9.5.2.Asia Pacific: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.5.3.Asia Pacific: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.4.Asia Pacific: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.5.Oral Transmucosal Drugs Market - China
    • 9.5.5.1.China: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.5.2.China.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.5.3.China: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.5.4.China: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.6.Oral Transmucosal Drugs Market - India
    • 9.5.6.1.India: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.6.2.India.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.6.3.India: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.6.4.India: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.7.Oral Transmucosal Drugs Market - Japan
    • 9.5.7.1.Japan: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.7.2.Japan.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.7.3.Japan: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.7.4.Japan: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.8.Oral Transmucosal Drugs Market - Malaysia
    • 9.5.8.1.Malaysia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.8.2.Malaysia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.8.3.Malaysia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.8.4.Malaysia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.9.Oral Transmucosal Drugs Market - Indonesia
    • 9.5.9.1.Indonesia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.9.2.Indonesia.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.9.3.Indonesia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.9.4.Indonesia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.5.10.Oral Transmucosal Drugs Market - South Korea
    • 9.5.10.1.South Korea: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.10.2.South Korea.: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.10.3.South Korea: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.10.4.South Korea: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• 9.6.Oral Transmucosal Drugs Market - Middle East & Africa
  • 9.6.1.Middle East & Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 9.6.2.Middle East & Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.6.3.Middle East & Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6.4.Middle East & Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.6.5.Oral Transmucosal Drugs Market - Saudi Arabia
    • 9.6.5.1.Saudi Arabia: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.5.2.Saudi Arabia: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.5.3.Saudi Arabia: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.5.4.Saudi Arabia: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.6.6.Oral Transmucosal Drugs Market - South Africa
    • 9.6.6.1.South Africa: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.6.2.South Africa: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.6.3.South Africa: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.6.4.South Africa: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.6.7.Oral Transmucosal Drugs Market - Israel
    • 9.6.7.1.Israel: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.7.2.Israel: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.7.3.Israel: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.7.4.Israel: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.6.8.Oral Transmucosal Drugs Market - UAE
    • 9.6.8.1.UAE: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.8.2.UAE: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.8.3.UAE: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.8.4.UAE: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
• 9.7.Oral Transmucosal Drugs Market - Latin America
  • 9.7.1.Latin America: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
  • 9.7.2.Latin America: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.7.3.Latin America: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7.4.Latin America: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.7.5.Oral Transmucosal Drugs Market - Mexico
    • 9.7.5.1.Mexico: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.5.2.Mexico: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.5.3.Mexico: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.5.4.Mexico: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.7.6.Oral Transmucosal Drugs Market - Brazil
    • 9.7.6.1.Brazil: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.6.2.Brazil: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.6.3.Brazil: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.6.4.Brazil: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)
  • 9.7.7.Oral Transmucosal Drugs Market - Argentina
    • 9.7.7.1.Argentina: Oral Transmucosal Drugs Market, by Product Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.7.2.Argentina: Oral Transmucosal Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.7.3.Argentina: Oral Transmucosal Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.7.4.Argentina: Oral Transmucosal Drugs Market, by Indication, 2019-2032 (USD Billion)

10.Competitive Landscape

• 10.1.Expansion and Acquisition Analysis
  • 10.1.1.Expansion
  • 10.1.2.Acquisitions
• 10.2.Partnerships/Collaborations/Agreements/Exhibitions

11.Company Profiles

• 11.1.Aquestive Therapeutics, Inc
  • 11.1.1.Company Overview
  • 11.1.2.Financial Performance
  • 11.1.3.Product Benchmarking
  • 11.1.4.Recent Development
• 11.2.C.L.Pharm Co., Ltd
  • 11.2.1.Company Overview
  • 11.2.2.Financial Performance
  • 11.2.3.Product Benchmarking
  • 11.2.4.Recent Development
• 11.3.GW Pharmaceuticals plc
  • 11.3.1.Company Overview
  • 11.3.2.Financial Performance
  • 11.3.3.Product Benchmarking
  • 11.3.4.Recent Development
• 11.4.IntelGenx Corp
  • 11.4.1.Company Overview
  • 11.4.2.Financial Performance
  • 11.4.3.Product Benchmarking
  • 11.4.4.Recent Development
• 11.5.IntelGenx Corp
  • 11.5.1.Company Overview
  • 11.5.2.Financial Performance
  • 11.5.3.Product Benchmarking
  • 11.5.4.Recent Development
• 11.6.Pfizer Inc
  • 11.6.1.Company Overview
  • 11.6.2.Financial Performance
  • 11.6.3.Product Benchmarking
  • 11.6.4.Recent Development
• 11.7.Seoul Pharmaceuticals
  • 11.7.1.Company Overview
  • 11.7.2.Financial Performance
  • 11.7.3.Product Benchmarking
  • 11.7.4.Recent Development
• 11.8.Shilpa Therapeutics
  • 11.8.1.Company Overview
  • 11.8.2.Financial Performance
  • 11.8.3.Product Benchmarking
  • 11.8.4.Recent Development
• 11.9.Sunovion Pharmaceuticals, Inc.
  • 11.9.1.Company Overview
  • 11.9.2.Financial Performance
  • 11.9.3.Product Benchmarking
  • 11.9.4.Recent Development
• 11.10.ZIM Laboratories Limited
  • 11.10.1.Company Overview
  • 11.10.2.Financial Performance
  • 11.10.3.Product Benchmarking
  • 11.10.4.Recent Development